Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Neoplasm Metastasis 3Breast Neoplasms 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Pancreatic Neoplasms 1Lung Neoplasms 1Localized Muscle Invasive Bladder Urothelial Carcinoma 1Liver Failure 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Biliary Tract Neoplasms 1Advanced Solid Tumors 1

Interventions

Radiotherapy 39pembrolizumab 37Carboplatin 37Cisplatin 34Paclitaxel 26Pemetrexed 24Docetaxel 18Nivolumab 17Magnetic Resonance Spectroscopy 17Gemcitabine 17Bevacizumab 17Specimen Handling 16Cyclophosphamide 15osimertinib 14Radiation 13Irinotecan 13Etoposide 13Erlotinib Hydrochloride 12durvalumab 11Topotecan 10Cetuximab 10Radiosurgery 9Immunoglobulin G 8Fluorouracil 8Everolimus 8Disulfides 8Celecoxib 8fludarabine 7Taxes 7Ipilimumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Lung Neoplasms × sacituzumab govitecan × Clear all
NCT04794699 2026-04-09

Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

IDEAYA Biosciences

Phase 1 Active not recruiting
169 enrolled
GenitourinaryThoracic

Urinary Bladder Neoplasms, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡